Tuoyu Cao

发表

FOXM1 contributes to taxane resistance by regulating UHRF1-controlled cancer cell stemness

Xuegong Fan, Yinke Yang, Youhong Liu, 2018, Cell Death & Disease.

UHRF1 promotes androgen receptor-regulated CDC6 transcription and anti-androgen receptor drug resistance in prostate cancer through KDM4C-Mediated chromatin modifications.

Youhong Liu, Xiong Li, Yuchong Peng, 2021, Cancer letters.

Norcantharidin promotes cancer radiosensitization through Cullin1 neddylation‐mediated CDC6 protein degradation

Yongbo Peng, Youhong Liu, Tanggang Deng, 2022, Molecular carcinogenesis.

USP7 is a novel Deubiquitinase sustaining PLK1 protein stability and regulating chromosome alignment in mitosis

Youhong Liu, Xiong Li, Yuchong Peng, 2019, Journal of Experimental & Clinical Cancer Research.

PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells

Lunquan Sun, Xuegong Fan, Z. Gong, 2018, Journal of experimental & clinical cancer research : CR.

FOXM1 contributes to taxane resistance by regulating UHRF1-controlled cancer cell stemness

Xuegong Fan, Yinke Yang, Youhong Liu, 2018, Cell Death & Disease.

PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells

Lunquan Sun, Xuegong Fan, Z. Gong, 2018, Journal of Experimental & Clinical Cancer Research.

Radiation-promoted CDC6 protein stability contributes to radioresistance by regulating senescence and epithelial to mesenchymal transition

Lunquan Sun, Y. Qiu, Xuegong Fan, 2018, Oncogene.

AKT1 regulates UHRF1 protein stability and promotes the resistance to abiraterone in prostate cancer

Yubing Ye, Youhong Liu, Tanggang Deng, 2023, Oncogenesis.

Correction to: PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/. BRCA1 DNA damage repair complex in prostate cancer cells

Lunquan Sun, Xuegong Fan, Z. Gong, 2022, Journal of experimental & clinical cancer research : CR.